eligibility_summary
Eligible: Advanced/metastatic CRC, epithelial ovarian/fallopian tube/primary peritoneal, endometrial, cervical, or NSCLC, >=1 prior systemic therapy with progression and no standard options, measurable disease, ECOG 0-1, adequate organs, archival (<=3 y) or fresh tumor tissue. Exclude: prior topo-1 ADC, unstable CNS mets, unresolved >G1 toxicities, recent systemic tx/radiation/surgery, active HBV/HCV/HIV or serious infection, ILD/pneumonitis. Other criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Trial: NCT06457997. Intervention: PHN-010, an intravenous antibody–drug conjugate (ADC). Drug type/mechanism: A monoclonal antibody linked to a cytotoxic payload, binds a tumor-associated surface antigen (target not disclosed), is internalized, and releases the payload to kill cancer cells. Based on exclusion of patients previously treated with topoisomerase I–based ADCs, PHN-010 likely carries a topoisomerase I inhibitor payload, causing DNA damage and apoptosis and potentially a bystander effect. Targets: Antigen-expressing tumor cells in advanced solid tumors (CRC, ovarian, endometrial, cervical, NSCLC). Pathways: Cell-surface antigen–mediated internalization and DNA replication/repair via topoisomerase I inhibition in proliferating cancer cells.